Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Nuvation Bio Inc. (NUVB)
USD5.78
-0.13 (-2.12%)
US NYSE Healthcare Biotechnology
Address
1500 Broadway 10036
New York City, NY, US
New York City, NY, US
CEO
David T. Hung
Website
nuvationbio.com
IPO
2020-08-26
CIK 1811063 ISIN US67080N1019
Also trades on
New York Stock Exchange · NUVB (USD)
New York Stock Exchange · NUVB-WT (USD)
Description
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD5.78
-0.13 (-2.12%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
6M
Beta
1.53
Float Shares
237.04M
Free Float %
68.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.63% | -5.74% | +3.48% | -17.79% | -3.45% | -46.88% | +121.40% | +193.83% | -56.88% | -52.40% | -52.40% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
5.78
Low
10.00
+73.2%
Consensus
12.40
+114.7%
Median
12.00
+107.8%
High
17.00
+194.4%
DCF (Unlevered)
3.44
-40.4%
DCF (Levered)
1.34
-76.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
90% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 2 | 0 |
| Buy | 7 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 9 |
12.11
+109.7%
|
| All Time | 17 |
9.76
+69.0%
|
Quality scores
Altman Z-Score
1.38
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+699.0% ★ Q1'26: +2,598.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+71.6% ★ Q1'26: +108.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-344.4% Q1'26: +6.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-303.6% Q1'26: +4.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: -7.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+27.1% Q1'26: +11.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.05× Q1'26: 0.56× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 4 EPS Ana. |
Dec 2027 6 Rev. Ana. 4 EPS Ana. |
Dec 2028 6 Rev. Ana. 5 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 1.44M (-100.0%)
|
7.87M
est: 2.17M (+262.9%)
|
62.90M
est: 58.86M (+6.9%)
|
203.16M
190.94M – 223.30M
+245.1% YoY
|
289.47M
285.57M – 293.37M
+42.5% YoY
|
387.07M
377.31M – 396.83M
+33.7% YoY
|
561.51M
507.77M – 620.81M
+45.1% YoY
|
849.71M
768.39M – 939.45M
+51.3% YoY
|
| EBITDA |
-75.58M
est: 287.0K (-26,434.6%)
|
-566.92M
est: 433.9K (-130,750.0%)
|
-190.95M
est: 11.77M (-1,722.0%)
|
40.63M
38.19M – 44.66M
+245.1% YoY
|
57.89M
57.11M – 58.67M
+42.5% YoY
|
77.41M
75.46M – 79.37M
+33.7% YoY
|
112.30M
101.55M – 124.16M
+45.1% YoY
|
169.94M
153.68M – 187.89M
+51.3% YoY
|
| EBIT |
-75.80M
est: 287.0K (-26,511.9%)
|
-567.60M
est: 433.9K (-130,907.4%)
|
-190.95M
est: 11.77M (-1,722.0%)
|
40.63M
38.19M – 44.66M
+245.1% YoY
|
57.89M
57.11M – 58.67M
+42.5% YoY
|
77.41M
75.46M – 79.37M
+33.7% YoY
|
112.30M
101.55M – 124.16M
+45.1% YoY
|
169.94M
153.68M – 187.89M
+51.3% YoY
|
| Net Income |
-75.80M
est: -778.75M (+90.3%)
|
-567.94M
est: -737.60M (+23.0%)
|
-204.63M
est: -202.06M (-1.3%)
|
-120.72M
-214.65M – -76.99M
+40.3% YoY
|
-99.26M
-102.03M – -78.55M
+17.8% YoY
|
-111.58M
-381.19M – 390.49M
-12.4% YoY
|
-4.10M
-4.66M – -3.59M
+96.3% YoY
|
186.48M
163.28M – 212.08M
+4,650.0% YoY
|
| SGA |
28.53M
est: 4.08M (+600.0%)
|
69.23M
est: 6.16M (+1,023.4%)
|
151.56M
est: 167.21M (-9.4%)
|
577.09M
542.40M – 634.31M
+245.1% YoY
|
822.29M
811.22M – 833.37M
+42.5% YoY
|
1.10B
1.07B – 1.13B
+33.7% YoY
|
1.60B
1.44B – 1.76B
+45.1% YoY
|
2.41B
2.18B – 2.67B
+51.3% YoY
|
| EPS |
-0.35
est: -2.27 (+84.6%)
|
-2.11
est: -2.12 (+0.5%)
|
-0.60
est: -0.59 (-2.3%)
|
-0.36
-0.63 – -0.23
+39.5% YoY
|
-0.26
-0.30 – -0.23
+26.1% YoY
|
-0.20
-1.12 – 1.14
+24.1% YoY
|
-0.01
-0.01 – -0.01
+94.0% YoY
|
0.55
0.48 – 0.62
+4,650.0% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-05 | Wedbush | Outperform | Outperform | Maintain |
| 2026-04-16 | Wedbush | Outperform | Outperform | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-85.95M
OE per share TTM
-0.26
Owner's Yield
-5.20%
Maintenance CapEx ratio
450.44%
Maint CapEx / Avg PPE
30.3%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
44
Total invested
10.45M
Insider transactions (90d)
2
Beneficial owners (>5%)
38
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | David Hung, M.D. | 59.65M | 27.40% | 59.65M | — | 59.65M | — | IN | — | 2021-02-19 | ↗ |
| 2 | Abigail P. Johnson | 32.28M | 14.90% | — | — | 32.28M | — | IN | Delaware | 2021-05-10 | ↗ |
| 3 | FMR LLC | 32.28M | 14.90% | 7.07M | — | 32.28M | — | HC | Delaware | 2021-05-10 | ↗ |
| 4 | Anne-Marie Paster | 28.21M | 13.00% | — | 28.21M | — | 28.21M | IN | — | 2021-02-19 | ↗ |
| 5 | Claudio Nessi | 28.21M | 13.00% | — | 28.21M | — | 28.21M | IN | — | 2021-02-19 | ↗ |
| 6 | Michelle Doig | 28.21M | 13.00% | — | 28.21M | — | 28.21M | IN | — | 2021-02-19 | ↗ |
| 7 | Omega Fund V GP Manager, Ltd. | 28.21M | 13.00% | — | 28.21M | — | 28.21M | OO | — | 2021-02-19 | ↗ |
| 8 | Omega Fund V GP, L.P. | 28.21M | 13.00% | — | 28.21M | — | 28.21M | PN | — | 2021-02-19 | ↗ |
| 9 | Omega Fund V, L.P. | 28.21M | 13.00% | 28.21M | — | 28.21M | — | PN | — | 2021-02-19 | ↗ |
| 10 | Otello Stampacchia | 28.21M | 13.00% | — | 28.21M | — | 28.21M | IN | — | 2021-02-19 | ↗ |
| 11 | Xiangmin Cui | 26.60M | 8.00% | — | 26.60M | — | 10.00 | IN | United States | 2024-09-10 | ↗ |
| 12 | Decheng Anbio Limited | 17.50M | 5.20% | — | 17.50M | — | 10.00 | OO | Hong Kong | 2024-09-10 | ↗ |
| 13 | (1) BlackRock, Inc. | 12.88M | 5.90% | 12.47M | — | 12.88M | — | HC | Delaware | 2024-01-29 | ↗ |
| 14 | David Kroin | 11.47M | 5.26% | — | 11.47M | — | — | HC, IN | Delaware | 2022-06-23 | ↗ |
| 15 | Deep Track Biotechnology Master Fund, Ltd. | 11.47M | 5.26% | — | 11.47M | — | — | CO | Delaware | 2022-06-23 | ↗ |
| 16 | Deep Track Capital, LP | 11.47M | 5.26% | — | 11.47M | — | — | IA, OO | Delaware | 2022-06-23 | ↗ |
| 17 | Decheng Capital Global Healthcare Fund (Master), LP | 7.79M | 2.30% | — | 7.79M | — | 10.00 | PN | Cayman Islands | 2024-09-10 | ↗ |
| 18 | Decheng Capital Global Healthcare GP, LLC | 7.79M | 2.30% | — | 7.79M | — | 10.00 | OO | Cayman Islands | 2024-09-10 | ↗ |
| 19 | Biotech Opportunity GP, LLC | 3.17M | 17.20% | — | 3.17M | — | 3.17M | OO | United States | 2021-02-08 | ↗ |
| 20 | EcoR1 Capital Fund Qualified, L.P. | 3.17M | 17.20% | — | 3.17M | — | 3.17M | PN | United States | 2021-02-08 | ↗ |
| 21 | EcoR1 Capital Fund, L.P. | 3.17M | 17.20% | — | 3.17M | — | 3.17M | PN | United States | 2021-02-08 | ↗ |
| 22 | EcoR1 Capital, LLC | 3.17M | 17.20% | — | 3.17M | — | 3.17M | IA, OO | United States | 2021-02-08 | ↗ |
| 23 | EcoR1 Panacea Holdings, LLC | 3.17M | 17.20% | — | 3.17M | — | 3.17M | OO | United States | 2021-02-08 | ↗ |
| 24 | EcoR1 Venture Opportunity Fund, L.P. | 3.17M | 17.20% | — | 3.17M | — | 3.17M | PN | United States | 2021-02-08 | ↗ |
| 25 | Oleg Nodelman | 3.17M | 17.20% | — | 3.17M | — | 3.17M | IN | United States | 2021-02-08 | ↗ |
| 26 | Decheng Capital China Life Sciences USD Fund III, L.P. | 1.31M | 0.40% | — | 1.31M | — | 10.00 | PN | Cayman Islands | 2024-09-10 | ↗ |
| 27 | Decheng Capital Management III (Cayman), LLC | 1.31M | 0.40% | — | 1.31M | — | 10.00 | OO | Cayman Islands | 2024-09-10 | ↗ |
| 28 | Adage Capital Advisors, L.L.C. | 500.0K | 3.36% | — | 500.0K | — | — | OO | Delaware | 2021-02-11 | ↗ |
| 29 | Adage Capital Partners GP, L.L.C. | 500.0K | 3.36% | — | 500.0K | — | — | OO | Delaware | 2021-02-11 | ↗ |
| 30 | Adage Capital Partners, L.P. | 500.0K | 3.36% | — | 500.0K | — | — | PN | Delaware | 2021-02-11 | ↗ |
| 31 | Phillip Gross | 500.0K | 3.36% | — | 500.0K | — | — | IN | United States | 2021-02-11 | ↗ |
| 32 | Robert Atchinson | 500.0K | 3.36% | — | 500.0K | — | — | IN | United States | 2021-02-11 | ↗ |
| 33 | Highbridge Capital Management, LLC | 357.8K | 2.41% | — | 357.8K | — | — | IA, OO | — | 2021-02-16 | ↗ |
| 34 | Highbridge Tactical Credit Master Fund, L.P. | 357.8K | 2.41% | — | 357.8K | — | — | PN | — | 2021-02-16 | ↗ |
| 35 | Castle Creek Arbitrage, LLC | 215.4K | 0.10% | — | 215.4K | — | 215.4K | IA | Delaware | 2022-02-11 | ↗ |
| 36 | Mr. Allan Weine | 215.4K | 0.10% | — | 215.4K | — | 215.4K | IN | United States | 2022-02-11 | ↗ |
| 37 | CC ARB West, LLC | 180.6K | 0.08% | — | 180.6K | — | 180.6K | PN | USA | 2022-02-11 | ↗ |
| 38 | CC Arbitrage, Ltd | 34.9K | 0.02% | — | 34.9K | — | 34.9K | OO | Cayman Islands | 2022-02-11 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
44
-183 vs prev Q
New positions
6
Closed positions
183
Increased
23
Reduced
8
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 1.25M +1.3M (+100.0%) | 11.20B +11.2B (+100.0%) | 0.37% +0.365 pp | 10.23% +10.229 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 2 | FMR LLC | 51.42M +854.5K (+1.7%) | 460.77M +273.7M (+146.3%) | 15.02% +0.178 pp | 0.02% +0.014 pp | USD5.76 +55.6% | 20 qtrs — |
| 3 | DECHENG CAPITAL LLC | 25.95M +— (+0.0%) | 232.55M +136.5M (+142.2%) | 7.58% -0.037 pp | 31.28% +14.528 pp | USD2.52 +255.6% | 7 qtrs — |
| 4 | BLACKROCK, INC. | 24.67M +65.6K (+0.3%) | 221.04M +130.0M (+142.8%) | 7.21% -0.016 pp | 0.00% +0.002 pp | USD2.23 +301.8% | 6 qtrs — |
| 5 | VANGUARD GROUP INC | 15.56M +101.0K (+0.7%) | 139.38M +82.2M (+143.7%) | 4.54% +0.008 pp | 0.00% +0.001 pp | USD5.72 +56.6% | 20 qtrs — |
| 6 | OMEGA FUND MANAGEMENT, LLC | 8.08M -750.0K (-8.5%) | 72.41M +39.7M (+121.6%) | 2.36% -0.232 pp | 25.27% +10.577 pp | USD10.45 -14.3% | 20 qtrs — |
| 7 | LAURION CAPITAL MANAGEMENT LP | 7.85M -1.9M (-19.1%) | 70.36M +34.4M (+95.9%) | 2.29% -0.555 pp | 2.62% +2.003 pp | USD2.42 +270.2% | 7 qtrs — |
| 8 | STATE STREET CORP | 5.86M -230.4K (-3.8%) | 52.49M +30.0M (+133.0%) | 1.71% -0.076 pp | 0.00% +0.001 pp | USD5.15 +74.0% | 20 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 5.71M -175.5K (-3.0%) | 51.19M +29.4M (+135.0%) | 1.67% -0.060 pp | 0.00% +0.002 pp | USD4.65 +92.7% | 20 qtrs — |
| 10 | TANG CAPITAL MANAGEMENT LLC | 3.86M -342.5K (-8.2%) | 34.56M +19.0M (+122.4%) | 1.13% -0.106 pp | 1.71% +1.109 pp | USD1.80 +397.8% | 9 qtrs — |
| 11 | ABRAMS CAPITAL MANAGEMENT, L.P. | 3.81M +— (+0.0%) | 34.15M +20.0M (+142.2%) | 1.11% -0.005 pp | 0.60% +0.373 pp | USD10.45 -14.3% | 20 qtrs — |
| 12 | BANK OF AMERICA CORP /DE/ | 3.81M +3.2M (+505.5%) | 34.13M +31.8M (+1,366.2%) | 1.11% +0.928 pp | 0.00% +0.002 pp | USD8.00 +12.0% | 19 qtrs — |
| 13 | REDMILE GROUP, LLC | 3.16M +132.2K (+4.4%) | 28.34M +17.1M (+152.7%) | 0.92% +0.034 pp | 2.09% +0.996 pp | USD10.39 -13.8% | 20 qtrs — |
| 14 | NUVEEN, LLC | 2.85M -1.7M (-37.5%) | 25.55M +8.7M (+51.2%) | 0.83% -0.507 pp | 0.01% +0.002 pp | USD3.11 +188.1% | 4 qtrs — |
| 15 | PRICE T ROWE ASSOCIATES INC /MD/ | 2.71M +2.4M (+852.2%) | 24.27M +23.2M (+2,204.8%) | 0.79% +0.708 pp | 0.00% +0.003 pp | USD8.36 +7.2% | 19 qtrs — |
| 16 | CAPTION MANAGEMENT, LLC | 2.53M +640.9K (+33.8%) | 22.71M +15.7M (+224.1%) | 0.74% +0.185 pp | 0.16% +0.101 pp | USD4.36 +105.5% | 3 qtrs — |
| 17 | DIMENSIONAL FUND ADVISORS LP | 2.07M -1.3M (-37.8%) | 18.51M +6.2M (+50.8%) | 0.60% -0.371 pp | 0.00% +0.001 pp | USD2.50 +258.4% | 15 qtrs — |
| 18 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2.02M -38.8K (-1.9%) | 18.07M +10.5M (+137.6%) | 0.59% -0.014 pp | 0.00% +0.002 pp | USD4.90 +82.9% | 20 qtrs — |
| 19 | NORTHERN TRUST CORP | 1.92M -195.9K (-9.3%) | 17.22M +9.4M (+119.8%) | 0.56% -0.060 pp | 0.00% +0.001 pp | USD5.37 +66.9% | 20 qtrs — |
| 20 | GOLDMAN SACHS GROUP INC | 1.70M +493.4K (+41.0%) | 15.20M +10.7M (+241.5%) | 0.50% +0.142 pp | 0.00% +0.001 pp | USD4.28 +109.3% | 20 qtrs — |
| 21 | AQR CAPITAL MANAGEMENT LLC | 1.67M -365.0K (-17.9%) | 14.96M +7.4M (+98.7%) | 0.49% -0.110 pp | 0.01% +0.003 pp | USD2.76 +224.6% | 8 qtrs — |
| 22 | CAPRICORN FUND MANAGERS LTD | 1.59M +1.6M (+100.0%) | 14.24M +14.2M (+100.0%) | 0.46% +0.464 pp | 3.43% +3.431 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 23 | KNOLL CAPITAL MANAGEMENT, LLC | 1.50M +473.6K (+46.2%) | 13.43M +7.9M (+142.2%) | 0.44% +0.137 pp | 6.16% +3.188 pp | USD4.04 +121.8% | 4 qtrs — |
| 24 | QUBE RESEARCH & TECHNOLOGIES LTD | 1.28M +1.3M (+100.0%) | 11.48M +11.5M (+100.0%) | 0.37% +0.374 pp | 0.01% +0.012 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 25 | MORGAN STANLEY | 1.28M -43.4K (-3.3%) | 11.43M +6.6M (+134.2%) | 0.37% -0.015 pp | 0.00% +0.000 pp | USD2.47 +262.8% | 20 qtrs — |
| 26 | ARMISTICE CAPITAL, LLC | 1.26M -1.0M (-45.0%) | 11.32M +2.8M (+33.3%) | 0.37% -0.305 pp | 0.13% +0.009 pp | USD3.32 +169.9% | 3 qtrs — |
| 27 | MARSHALL WACE, LLP | 1.23M +1.0M (+487.8%) | 11.06M +10.3M (+1,323.3%) | 0.36% +0.299 pp | 0.01% +0.009 pp | USD7.77 +15.3% | 3 qtrs — |
| 28 | INVESCO LTD. | 1.19M +687.6K (+138.2%) | 10.62M +8.8M (+476.8%) | 0.35% +0.200 pp | 0.00% +0.001 pp | USD6.55 +36.8% | 19 qtrs — |
| 29 | WOODLINE PARTNERS LP | 957.9K +2.5K (+0.3%) | 8.58M +5.0M (+142.8%) | 0.28% -0.001 pp | 0.03% +0.017 pp | USD3.71 +141.5% | 2 qtrs — |
| 30 | NEWEDGE ADVISORS, LLC | 952.2K +952.2K (+100.0%) | 8.53M +8.5M (+100.0%) | 0.28% +0.278 pp | 0.03% +0.031 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 31 | WELLINGTON MANAGEMENT GROUP LLP | 900.0K +31.5K (+3.6%) | 8.06M +4.9M (+150.9%) | 0.26% +0.008 pp | 0.00% +0.001 pp | USD3.06 +192.8% | 7 qtrs — |
| 32 | D. E. SHAW & CO., INC. | 875.8K +875.8K (+100.0%) | 7.85M +7.8M (+100.0%) | 0.26% +0.256 pp | 0.00% +0.004 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 33 | TANAKA CAPITAL MANAGEMENT INC | 841.6K +156.5K (+22.8%) | 7.54M +5.0M (+197.5%) | 0.25% +0.045 pp | 13.76% +9.191 pp | USD4.68 +91.5% | 2 qtrs — |
| 34 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 819.6K +355.6K (+76.6%) | 7.34M +5.6M (+327.8%) | 0.24% +0.103 pp | 0.00% +0.003 pp | USD5.98 +49.8% | 2 qtrs — |
| 35 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 743.0K +728.9K (+5,169.5%) | 6.66M +6.6M (+12,660.7%) | 0.22% +0.213 pp | 0.00% +0.001 pp | USD8.83 +1.5% | 3 qtrs — |
| 36 | TWO SIGMA INVESTMENTS, LP | 735.9K -1.6M (-69.0%) | 6.59M -2.2M (-25.0%) | 0.21% -0.483 pp | 0.01% -0.004 pp | USD2.82 +217.7% | 16 qtrs — |
| 37 | MILLENNIUM MANAGEMENT LLC | 711.5K -4.1M (-85.3%) | 6.38M -11.6M (-64.5%) | 0.21% -1.216 pp | 0.00% -0.005 pp | USD2.07 +332.9% | 15 qtrs — |
| 38 | BNP PARIBAS ARBITRAGE, SNC | 702.0K +650.3K (+1,257.8%) | 6.29M +6.1M (+3,188.2%) | 0.21% +0.190 pp | 0.00% +0.003 pp | USD8.52 +5.2% | 5 qtrs — |
| 39 | BANK OF NEW YORK MELLON CORP | 687.2K -40.7K (-5.6%) | 6.16M +3.5M (+128.6%) | 0.20% -0.013 pp | 0.00% +0.001 pp | USD5.13 +74.7% | 20 qtrs — |
| 40 | UBS GROUP AG | 615.4K -292.7K (-32.2%) | 5.51M +2.2M (+64.1%) | 0.18% -0.087 pp | 0.00% +0.000 pp | USD3.05 +193.8% | 20 qtrs — |
| 41 | ACT CAPITAL MANAGEMENT, LLC | 610.5K +610.5K (+100.0%) | 5.47M +5.5M (+100.0%) | 0.18% +0.178 pp | 4.42% +4.423 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 42 | JPMORGAN CHASE & CO | 595.0K -80.6K (-11.9%) | 5.33M +2.8M (+113.3%) | 0.17% -0.025 pp | 0.00% +0.000 pp | USD3.50 +156.0% | 19 qtrs — |
| 43 | NEO IVY CAPITAL MANAGEMENT | 587.7K +587.7K (+100.0%) | 5.27M +5.3M (+100.0%) | 0.17% +0.172 pp | 0.83% +0.832 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 44 | CAXTON ASSOCIATES LLP | 584.9K +392.7K (+204.2%) | 5.24M +4.5M (+636.7%) | 0.17% +0.114 pp | 0.10% +0.086 pp | USD7.23 +23.9% | 2 qtrs — |
| 45 | SUMMITTX CAPITAL, L.P. | 578.3K +578.3K (+100.0%) | 5.18M +5.2M (+100.0%) | 0.17% +0.169 pp | 0.16% +0.156 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 46 | PALO ALTO INVESTORS LP | 538.1K -482.5K (-47.3%) | 4.82M +1.0M (+27.7%) | 0.16% -0.142 pp | 0.67% -0.028 pp | USD3.69 +142.8% | 8 qtrs — |
| 47 | JANE STREET GROUP, LLC | 530.1K -1.8M (-77.2%) | 4.75M -3.8M (-44.7%) | 0.15% -0.527 pp | 0.00% -0.001 pp | USD3.70 +142.2% | 2 qtrs — |
| 48 | UBS ASSET MANAGEMENT AMERICAS INC | 521.0K +150.2K (+40.5%) | 4.67M +3.3M (+240.2%) | 0.15% +0.043 pp | 0.00% +0.001 pp | USD4.32 +107.4% | 7 qtrs — |
| 49 | HENNION & WALSH ASSET MANAGEMENT, INC. | 445.3K +106.0K (+31.2%) | 3.99M +2.7M (+217.8%) | 0.13% +0.031 pp | 0.14% +0.092 pp | USD4.17 +114.9% | 3 qtrs — |
| 50 | BARCLAYS PLC | 439.3K -779.0K (-63.9%) | 3.94M +1.1M (+41.1%) | 0.13% -0.229 pp | 0.00% +0.000 pp | USD3.12 +187.2% | 16 qtrs — |
| 51 | SWISS NATIONAL BANK | 437.4K +75.6K (+20.9%) | 3.92M +2.6M (+192.8%) | 0.13% +0.022 pp | 0.00% +0.002 pp | USD3.99 +124.6% | 7 qtrs — |
| 52 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 408.9K +408.9K (+100.0%) | 3.66M +3.7M (+100.0%) | 0.12% +0.119 pp | 0.01% +0.013 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 53 | EAM INVESTORS, LLC | 404.0K +404.0K (+100.0%) | 3.62M +3.6M (+100.0%) | 0.12% +0.118 pp | 0.40% +0.403 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 54 | TWO SIGMA ADVISERS, LP | 393.1K -478.4K (-54.9%) | 3.52M +297.6K (+9.2%) | 0.11% -0.141 pp | 0.01% +0.000 pp | USD2.79 +221.1% | 16 qtrs — |
| 55 | TD ASSET MANAGEMENT INC | 312.4K +312.4K (+100.0%) | 2.80M +2.8M (+100.0%) | 0.09% +0.091 pp | 0.00% +0.002 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 56 | RHUMBLINE ADVISERS | 308.2K -2.0K (-0.6%) | 2.76M +1.6M (+140.6%) | 0.09% -0.001 pp | 0.00% +0.001 pp | USD3.84 +133.3% | 19 qtrs — |
| 57 | ALGERT GLOBAL LLC | 291.1K +291.1K (+100.0%) | 2.61M +2.6M (+100.0%) | 0.09% +0.085 pp | 0.04% +0.041 pp | USD8.96 +0.0% | 16 qtrs — |
| 58 | INTELLECTUS PARTNERS, LLC | 285.4K -46.4K (-14.0%) | 2.56M +1.3M (+108.3%) | 0.08% -0.014 pp | 0.49% +0.256 pp | USD5.56 +61.2% | 20 qtrs — |
| 59 | ALPS ADVISORS INC | 280.9K +116.9K (+71.2%) | 2.52M +1.9M (+314.7%) | 0.08% +0.034 pp | 0.01% +0.011 pp | USD5.28 +69.7% | 5 qtrs — |
| 60 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 278.8K +193.0K (+224.9%) | 2.49M +2.2M (+685.6%) | 0.08% +0.056 pp | 0.00% +0.002 pp | USD7.38 +21.4% | 19 qtrs — |
| 61 | IEQ CAPITAL, LLC | 274.1K -24.3K (-8.1%) | 2.46M +1.4M (+122.4%) | 0.08% -0.008 pp | 0.01% +0.004 pp | USD3.08 +190.9% | 5 qtrs — |
| 62 | WELLS FARGO & COMPANY/MN | 271.9K +82.6K (+43.6%) | 2.44M +1.7M (+247.8%) | 0.08% +0.024 pp | 0.00% +0.000 pp | USD4.46 +100.9% | 20 qtrs — |
| 63 | BEACON POINTE ADVISORS, LLC | 259.2K +97.6K (+60.4%) | 2.32M +1.7M (+288.4%) | 0.08% +0.028 pp | 0.02% +0.011 pp | USD4.66 +92.3% | 5 qtrs — |
| 64 | STATE OF WISCONSIN INVESTMENT BOARD | 257.0K +73.5K (+40.0%) | 2.30M +1.6M (+239.1%) | 0.08% +0.021 pp | 0.01% +0.004 pp | USD5.00 +79.2% | 7 qtrs — |
| 65 | CI PRIVATE WEALTH, LLC | 254.1K +254.1K (+100.0%) | 2.28M +2.3M (+100.0%) | 0.07% +0.074 pp | 0.00% +0.003 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 66 | NEOS INVESTMENT MANAGEMENT LLC | 247.5K -5.0K (-2.0%) | 2.22M +1.3M (+137.4%) | 0.07% -0.002 pp | 0.01% +0.006 pp | USD2.73 +228.2% | 3 qtrs — |
| 67 | TEMA ETFS LLC | 243.8K -8.7K (-3.4%) | 2.18M +1.3M (+133.8%) | 0.07% -0.003 pp | 0.17% +0.092 pp | USD2.73 +228.2% | 3 qtrs — |
| 68 | ALLIANCEBERNSTEIN L.P. | 229.1K +20.5K (+9.8%) | 2.05M +1.3M (+166.0%) | 0.07% +0.006 pp | 0.00% +0.000 pp | USD7.24 +23.8% | 19 qtrs — |
| 69 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 213.7K +51.2K (+31.5%) | 1.91M +1.3M (+218.5%) | 0.06% +0.015 pp | 0.00% +0.001 pp | USD4.73 +89.4% | 19 qtrs — |
| 70 | LEGAL & GENERAL GROUP PLC | 192.9K -29.8K (-13.4%) | 1.73M +905.2K (+110.0%) | 0.06% -0.009 pp | 0.00% +0.000 pp | USD2.97 +201.7% | 19 qtrs — |
| 71 | CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 192.0K +192.0K (+100.0%) | 1.72M +1.7M (+100.0%) | 0.06% +0.056 pp | 0.00% +0.005 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 72 | DEUTSCHE BANK AG\ | 190.8K +55.4K (+40.9%) | 1.71M +1.2M (+241.2%) | 0.06% +0.016 pp | 0.00% +0.000 pp | USD5.30 +69.1% | 19 qtrs — |
| 73 | TREXQUANT INVESTMENT LP | 186.9K +186.9K (+100.0%) | 1.67M +1.7M (+100.0%) | 0.05% +0.055 pp | 0.01% +0.015 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 74 | DARK FOREST CAPITAL MANAGEMENT LP | 185.8K +185.8K (+100.0%) | 1.67M +1.7M (+100.0%) | 0.05% +0.054 pp | 0.08% +0.076 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 75 | JUMP FINANCIAL, LLC | 169.6K +169.6K (+100.0%) | 1.52M +1.5M (+100.0%) | 0.05% +0.050 pp | 0.02% +0.019 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 76 | PALUMBO WEALTH MANAGEMENT LLC | 163.8K +29.9K (+22.3%) | 1.47M +972.0K (+196.2%) | 0.05% +0.009 pp | 0.36% +0.204 pp | USD3.77 +137.7% | 8 qtrs — |
| 77 | METLIFE INVESTMENT MANAGEMENT, LLC | 138.2K -9.7K (-6.5%) | 1.24M +691.0K (+126.3%) | 0.04% -0.003 pp | 0.01% +0.003 pp | USD3.30 +171.5% | 19 qtrs — |
| 78 | CITADEL ADVISORS LLC | 135.0K -2.2M (-94.1%) | 1.21M -7.3M (-85.8%) | 0.04% -0.637 pp | 0.00% -0.001 pp | USD3.76 +138.3% | 20 qtrs — |
| 79 | WEXFORD CAPITAL LP | 130.0K +99.7K (+328.6%) | 1.16M +1.1M (+938.1%) | 0.04% +0.029 pp | 0.22% +0.209 pp | USD7.44 +20.4% | 13 qtrs — |
| 80 | AMI ASSET MANAGEMENT CORP | 126.5K +126.5K (+100.0%) | 1.13M +1.1M (+100.0%) | 0.04% +0.037 pp | 0.06% +0.064 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 81 | VERITION FUND MANAGEMENT LLC | 125.2K +125.2K (+100.0%) | 1.12M +1.1M (+100.0%) | 0.04% +0.037 pp | 0.00% +0.004 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 82 | CRESSET ASSET MANAGEMENT, LLC | 118.6K -25.1K (-17.4%) | 1.06M +531.4K (+99.9%) | 0.03% -0.008 pp | 0.00% +0.002 pp | USD9.01 -0.6% | 20 qtrs — |
| 83 | MERIDIAN WEALTH MANAGEMENT, LLC | 113.6K +4.2K (+3.8%) | 1.02M +612.9K (+151.5%) | 0.03% +0.001 pp | 0.04% +0.020 pp | USD3.22 +178.3% | 7 qtrs — |
| 84 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 112.0K -2.9K (-2.5%) | 1.00M +578.5K (+136.0%) | 0.03% -0.001 pp | 0.00% +0.001 pp | USD2.68 +234.3% | 7 qtrs — |
| 85 | JANUS HENDERSON GROUP PLC | 108.4K +31.7K (+41.3%) | 971.8K +688.4K (+242.9%) | 0.03% +0.009 pp | 0.00% +0.000 pp | USD4.86 +84.4% | 7 qtrs — |
| 86 | CREATIVE PLANNING | 107.7K +38.2K (+54.9%) | 965.1K +707.8K (+275.1%) | 0.03% +0.011 pp | 0.00% +0.001 pp | USD4.92 +82.1% | 7 qtrs — |
| 87 | WEALTHCARE ADVISORY PARTNERS LLC | 107.0K +107.0K (+100.0%) | 958.3K +958.3K (+100.0%) | 0.03% +0.031 pp | 0.02% +0.019 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 88 | CWM, LLC | 102.4K +50.0 (+0.0%) | 917.0K +538.0K (+142.0%) | 0.03% 0.000 pp | 0.00% +0.001 pp | USD3.11 +188.1% | 7 qtrs — |
| 89 | VOYA INVESTMENT MANAGEMENT LLC | 99.8K +53.2K (+114.1%) | 894.0K +721.6K (+418.5%) | 0.03% +0.016 pp | 0.00% +0.001 pp | USD7.19 +24.6% | 19 qtrs — |
| 90 | CERITY PARTNERS LLC | 96.7K -1.2K (-1.3%) | 866.0K +503.8K (+139.1%) | 0.03% -0.001 pp | 0.00% +0.001 pp | USD2.81 +218.9% | 5 qtrs — |
| 91 | INTECH INVESTMENT MANAGEMENT LLC | 90.4K -7.4K (-7.6%) | 810.1K +448.2K (+123.8%) | 0.03% -0.002 pp | 0.01% +0.004 pp | USD2.15 +316.7% | 6 qtrs — |
| 92 | SEI INVESTMENTS CO | 84.2K +69.3K (+466.2%) | 754.1K +699.1K (+1,271.2%) | 0.02% +0.020 pp | 0.00% +0.001 pp | USD8.03 +11.6% | 2 qtrs — |
| 93 | VIRTUS INVESTMENT ADVISERS, INC. | 81.1K +18.2K (+29.0%) | 726.4K +493.8K (+212.3%) | 0.02% +0.005 pp | 0.20% +0.131 pp | USD3.64 +146.2% | 4 qtrs — |
| 94 | STATE OF NEW JERSEY COMMON PENSION FUND D | 75.7K +75.7K (+100.0%) | 678.4K +678.4K (+100.0%) | 0.02% +0.022 pp | 0.00% +0.003 pp | USD8.96 +0.0% | 1 qtrs NEW |
| 95 | NEW YORK STATE COMMON RETIREMENT FUND | 68.7K +19.7K (+40.2%) | 615.8K +434.4K (+239.5%) | 0.02% +0.006 pp | 0.00% +0.001 pp | USD8.35 +7.3% | 19 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 98 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Pharmaceuticals ETF XPH | 1.93% | 9.11M | 0.35% |
| 2 | iShares Genomics Immunology and Healthcare ETF IDNA | 1.58% | 3.09M | 0.47% |
| 3 | Virtus Biotech ETF BBP | 1.52% | 1.50M | 0.34% |
| 4 | Tema Oncology ETF CANC | 1.19% | 1.70M | 0.75% |
| 5 | ALPS Medical Breakthroughs ETF SBIO | 1.03% | 2.20M | 0.50% |
| 6 | Invesco Dorsey Wright Healthcare Momentum ETF PTH | 0.95% | 1.60M | 0.72% |
| 7 | Direxion Daily Pharmaceutical & Medical Bull 3X ETF PILL | 0.40% | 93.6K | 1.22% |
| 8 | iShares Micro-Cap ETF IWC | 0.33% | 4.91M | 0.60% |
| 9 | iShares U.S. Pharmaceuticals ETF IHE | 0.32% | 4.27M | 0.38% |
| 10 | American Century Small Cap Growth Insights ETF ACSG | 0.26% | 65.8K | 0.49% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.42
Bearish
Ratio by volume
0.51
Neutral
Buys
8
Sells
19
Shares acquired
864.1K
Shares disposed
1.71M
Cash buys
—
Cash sales
9.00
Net activity
-845,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-17 | Wentworth Kerry | Officer | M-Exempt | D | Stock Option (Right to Buy) | 36,750 | 2.93 | 107.7K | 215,250 | D | ↗ |
| 2026-04-17 | Liu Dongfang | Officer | M-Exempt | D | Stock Option (Right to Buy) | 50,000 | 1.94 | 97.0K | 430,000 | D | ↗ |
| 2026-04-06 | Wentworth Kerry | Officer | M-Exempt | D | Stock Option (Right to Buy) | 100,000 | 1.87 | 187.0K | 400,000 | D | ↗ |
| 2026-02-27 | Wentworth Kerry | Officer | A-Award | A | Stock Option (Right to Buy) | 748,130 | 5.91 | 4.42M | 748,130 | D | ↗ |
| 2026-02-27 | Sjogren Colleen | Officer | A-Award | A | Stock Option (Right to Buy) | 748,130 | 5.91 | 4.42M | 748,130 | D | ↗ |
| 2026-02-27 | Sauvage Philippe | Officer | A-Award | A | Stock Option (Right to Buy) | 748,130 | 5.91 | 4.42M | 748,130 | D | ↗ |
| 2026-02-27 | Markel Stacy | Officer | A-Award | A | Stock Option (Right to Buy) | 748,130 | 5.91 | 4.42M | 748,130 | D | ↗ |
| 2026-02-27 | Makunje Moses | Officer | A-Award | A | Class A Common Stock | 50,761 | 0.00 | — | 68,137 | D | ↗ |
| 2026-02-27 | Liu Dongfang | Officer | A-Award | A | Stock Option (Right to Buy) | 748,130 | 5.91 | 4.42M | 748,130 | D | ↗ |
| 2026-02-27 | Hung David | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 1,995,012 | 5.91 | 11.79M | 1,995,012 | D | ↗ |
| 2026-02-27 | Hattersley Gary | Officer | A-Award | A | Stock Option (Right to Buy) | 748,130 | 5.91 | 4.42M | 748,130 | D | ↗ |
| 2026-02-27 | Hanley David C. | Officer | A-Award | A | Stock Option (Right to Buy) | 748,130 | 5.91 | 4.42M | 748,130 | D | ↗ |
| 2026-02-27 | Cui Xiangmin | Director | A-Award | A | Stock Option (Right to Buy) | 74,813 | 5.91 | 442.1K | 74,813 | D | ↗ |
| 2025-12-01 | Liu Dongfang | Officer | S-Sale | D | Class A Common Stock | 150,000 | 7.82 | 1.17M | 18,000 | D | ↗ |
| 2025-11-26 | Liu Dongfang | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 3.61 | 36.1K | 470,000 | D | ↗ |
| 2025-11-25 | Liu Dongfang | Officer | M-Exempt | D | Stock Option (Right to Buy) | 10,000 | 3.61 | 36.1K | 480,000 | D | ↗ |
| 2025-11-20 | Liu Dongfang | Officer | M-Exempt | D | Stock Option (Right to Buy) | 20,000 | 1.87 | 37.4K | 450,000 | D | ↗ |
| 2025-11-20 | Hattersley Gary | Officer | M-Exempt | A | Class A Common Stock | 69,051 | 1.74 | 120.1K | 69,051 | D | ↗ |
| 2025-11-19 | Liu Dongfang | Officer | S-Sale | D | Class A Common Stock | 15,000 | 5.10 | 76.6K | 18,000 | D | ↗ |
| 2025-11-19 | Hanley David C. | Officer | M-Exempt | A | Class A Common Stock | 200,000 | 1.87 | 374.0K | 224,000 | D | ↗ |
| 2025-11-17 | Liu Dongfang | Officer | M-Exempt | D | Stock Option (Right to Buy) | 15,000 | 1.87 | 28.1K | 485,000 | D | ↗ |
| 2025-10-27 | Hattersley Gary | Officer | M-Exempt | A | Class A Common Stock | 100,000 | 1.74 | 174.0K | 100,000 | D | ↗ |
| 2025-08-11 | Mashal Robert | Director | G-Gift | D | Stock Option (Right to Buy) | 350,001 | 1.55 | 542.5K | 391,178 | D | ↗ |
| 2025-06-18 | Markel Stacy | Officer | P-Purchase | A | Class A Common Stock | 10,000 | 1.71 | 17.1K | 29,591 | D | ↗ |
| 2025-06-17 | Sauvage Philippe | Officer | P-Purchase | A | Class A Common Stock | 4,000 | 1.79 | 7.2K | 9,902 | D | ↗ |
| 2025-06-16 | Wentworth Kerry | Officer | P-Purchase | A | Class A Common Stock | 24,000 | 1.80 | 43.2K | 50,000 | D | ↗ |
| 2025-06-16 | Sjogren Colleen | Officer | P-Purchase | A | Class A Common Stock | 50,000 | 1.81 | 90.4K | 81,000 | D | ↗ |
| 2025-06-16 | Sauvage Philippe | Officer | P-Purchase | A | Class A Common Stock | 3,300 | 1.84 | 6.1K | 5,902 | D | ↗ |
| 2025-06-16 | Hung David | Director / Officer / 10% Owner | P-Purchase | A | Class A Common Stock | 500,000 | 1.79 | 893.5K | 59,281,054 | D | ↗ |
| 2025-05-21 | VERNON W ANTHONY | Director | A-Award | A | Stock Option (Right to Buy) | 292,983 | 2.03 | 594.8K | 292,983 | D | ↗ |
| 2025-05-21 | Mashal Robert | Director | A-Award | A | Stock Option (Right to Buy) | 292,983 | 2.03 | 594.8K | 292,983 | D | ↗ |
| 2025-05-21 | FALBERG KATHRYN E | Director | A-Award | A | Stock Option (Right to Buy) | 292,983 | 2.03 | 594.8K | 292,983 | D | ↗ |
| 2025-05-21 | Bazemore Robert B | Director | A-Award | A | Stock Option (Right to Buy) | 292,983 | 2.03 | 594.8K | 292,983 | D | ↗ |
| 2025-05-21 | BLICKENSTAFF KIM D | Director | A-Award | A | Stock Option (Right to Buy) | 292,983 | 2.03 | 594.8K | 292,983 | D | ↗ |
| 2025-05-02 | Liu Dongfang | Officer | M-Exempt | A | Class A Common Stock | 20,000 | 1.94 | 38.8K | 32,000 | D | ↗ |
| 2025-04-07 | Hung David | Director / Officer / 10% Owner | P-Purchase | A | Class A Common Stock | 300,000 | 1.63 | 487.5K | 58,781,054 | D | ↗ |
| 2025-04-04 | Hung David | Director / Officer / 10% Owner | P-Purchase | A | Class A Common Stock | 200,000 | 1.66 | 332.7K | 58,481,054 | D | ↗ |
| 2025-04-01 | Mashal Robert | Director | P-Purchase | A | Class A Common Stock | 98,900 | 1.67 | 165.2K | 200,000 | I | ↗ |
| 2025-02-28 | Wentworth Kerry | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.97 | 985.0K | 500,000 | D | ↗ |
| 2025-02-28 | Sjogren Colleen | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.97 | 985.0K | 500,000 | D | ↗ |
| 2025-02-28 | Sauvage Philippe | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.97 | 985.0K | 500,000 | D | ↗ |
| 2025-02-28 | Markel Stacy | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.97 | 985.0K | 500,000 | D | ↗ |
| 2025-02-28 | Makunje Moses | Officer | A-Award | A | Stock Option (Right to Buy) | 250,000 | 1.97 | 492.5K | 250,000 | D | ↗ |
| 2025-02-28 | Liu Dongfang | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.97 | 985.0K | 500,000 | D | ↗ |
| 2025-02-28 | Hung David | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 2,000,000 | 1.97 | 3.94M | 2,000,000 | D | ↗ |
| 2025-02-28 | Hattersley Gary | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.97 | 985.0K | 500,000 | D | ↗ |
| 2025-02-28 | Hanley David C. | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.97 | 985.0K | 500,000 | D | ↗ |
| 2024-11-11 | Wang Junyuan Jerry | Director / Officer | S-Sale | D | Class A Common Stock | 56,361 | 2.89 | 162.9K | 3,866,228 | D | ↗ |
| 2024-10-08 | Mashal Robert | Director | P-Purchase | A | Class A Common Stock | 99,981 | 2.20 | 220.0K | 100,000 | I | ↗ |
| 2024-10-07 | Sauvage Philippe | Officer | A-Award | A | Stock Option (Right to Buy) | 750,000 | 2.17 | 1.63M | 750,000 | D | ↗ |
| 2024-09-04 | Wang Junyuan Jerry | Director / Officer | C-Conversion | A | Class A Common Stock | 2,543,600 | 0.00 | — | 3,922,589 | — | ↗ |
| 2024-09-04 | Cui Xiangmin | Director | C-Conversion | A | Class A Common Stock | 967,100 | 0.00 | — | 1,281,206 | — | ↗ |
| 2024-09-03 | Wang Junyuan Jerry | Director / Officer | A-Award | A | Series A Preferred Stock | 16,957 | 0.00 | — | 16,957 | — | ↗ |
| 2024-09-03 | VERNON W ANTHONY | Director | A-Award | A | Stock Option (Right to Buy) | 200,801 | 2.98 | 598.4K | 200,801 | — | ↗ |
| 2024-09-03 | FALBERG KATHRYN E | Director | A-Award | A | Stock Option (Right to Buy) | 200,801 | 2.98 | 598.4K | 200,801 | — | ↗ |
| 2024-09-03 | Cui Xiangmin | Director | A-Award | A | Series A Preferred Stock | 51,579 | 0.00 | — | 51,579 | — | ↗ |
| 2024-09-03 | Bazemore Robert B | Director | A-Award | A | Stock Option (Right to Buy) | 200,801 | 2.98 | 598.4K | 200,801 | — | ↗ |
| 2024-09-03 | BLICKENSTAFF KIM D | Director | A-Award | A | Stock Option (Right to Buy) | 200,801 | 2.98 | 598.4K | 200,801 | — | ↗ |
| 2024-06-25 | Cui Xiangmin | Director | P-Purchase | A | Class A Common Stock | 277,895 | 2.97 | 825.3K | 2,453,131 | — | ↗ |
| 2024-06-24 | Cui Xiangmin | Director | P-Purchase | A | Class A Common Stock | 336,874 | 2.98 | 1.00M | 2,175,236 | — | ↗ |
| 2024-06-21 | Cui Xiangmin | Director | P-Purchase | A | Class A Common Stock | 75,411 | 3.00 | 226.2K | 1,838,362 | — | ↗ |
| 2024-06-20 | Cui Xiangmin | Director | P-Purchase | A | Class A Common Stock | 87,715 | 2.99 | 262.3K | 1,762,951 | — | ↗ |
| 2024-06-11 | BLICKENSTAFF KIM D | Director | P-Purchase | A | Class A Common Stock | 172,189 | 2.90 | 500.1K | 172,189 | — | ↗ |
| 2024-05-24 | WELCH DANIEL G | Director | M-Exempt | D | Stock Option (Right to Buy) | 293,203 | 1.74 | 510.2K | 19,547 | — | ↗ |
| 2024-04-09 | Wang Junyuan Jerry | Director / Officer | A-Award | A | Class A Common Stock | 1,378,989 | 0.00 | — | 1,378,989 | — | ↗ |
| 2024-04-09 | Sjogren Colleen | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 3.23 | 1.62M | 500,000 | — | ↗ |
| 2024-04-09 | Cui Xiangmin | Director | A-Award | A | Class A Common Stock | 4,183,002 | 0.00 | — | 4,183,002 | — | ↗ |
| 2024-03-27 | Sjogren Colleen | Officer | — | D | Class A Common Stock | 0 | 0.00 | — | 25,000 | — | ↗ |
| 2024-02-29 | Wentworth Kerry | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.87 | 935.0K | 500,000 | — | ↗ |
| 2024-02-29 | Markel Stacy | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.87 | 935.0K | 500,000 | — | ↗ |
| 2024-02-29 | Makunje Moses | Officer | A-Award | A | Class A Common Stock | 250,000 | 1.87 | 467.5K | 250,000 | — | ↗ |
| 2024-02-29 | Liu Dongfang | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.87 | 935.0K | 500,000 | — | ↗ |
| 2024-02-29 | Hung David | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 2,000,000 | 1.87 | 3.74M | 2,000,000 | — | ↗ |
| 2024-02-29 | Hattersley Gary | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.87 | 935.0K | 500,000 | — | ↗ |
| 2024-02-29 | Hanley David C. | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.87 | 935.0K | 500,000 | — | ↗ |
| 2024-01-08 | Mashal Robert | Director | A-Award | A | Stock Option (Right to Buy) | 741,179 | 1.55 | 1.15M | 741,179 | — | ↗ |
| 2023-11-27 | Makunje Moses | Officer | — | D | Stock Option (Right to Buy) | 112,704 | 4.60 | 518.4K | 0 | — | ↗ |
| 2023-09-21 | NODELMAN OLEG | Director | P-Purchase | A | Class A Common Stock | 53,000 | 1.36 | 72.1K | 12,674,775 | — | ↗ |
| 2023-09-20 | NODELMAN OLEG | Director | P-Purchase | A | Class A Common Stock | 117,100 | 1.36 | 159.5K | 12,621,775 | — | ↗ |
| 2023-09-19 | NODELMAN OLEG | Director | P-Purchase | A | Class A Common Stock | 5,143,000 | 1.26 | 6.46M | 12,504,675 | — | ↗ |
| 2023-05-15 | WELCH DANIEL G | Director | A-Award | A | Stock Option (Right to Buy) | 366,744 | 1.64 | 601.5K | 366,744 | — | ↗ |
| 2023-05-15 | VERNON W ANTHONY | Director | A-Award | A | Stock Option (Right to Buy) | 366,744 | 1.64 | 601.5K | 366,744 | — | ↗ |
| 2023-05-15 | FALBERG KATHRYN E | Director | A-Award | A | Stock Option (Right to Buy) | 366,744 | 1.64 | 601.5K | 366,744 | — | ↗ |
| 2023-05-15 | Bazemore Robert B | Director | A-Award | A | Stock Option (Right to Buy) | 366,744 | 1.64 | 601.5K | 366,744 | — | ↗ |
| 2023-05-15 | BLICKENSTAFF KIM D | Director | A-Award | A | Stock Option (Right to Buy) | 366,744 | 1.64 | 601.5K | 366,744 | — | ↗ |
| 2023-02-28 | Wentworth Kerry | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 1.94 | 776.0K | 400,000 | — | ↗ |
| 2023-02-28 | Markel Stacy | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.94 | 970.0K | 500,000 | — | ↗ |
| 2023-02-28 | Liu Dongfang | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.94 | 970.0K | 500,000 | — | ↗ |
| 2023-02-28 | Hung David | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 2,500,000 | 1.94 | 4.85M | 2,500,000 | — | ↗ |
| 2023-02-28 | Hattersley Gary | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.94 | 970.0K | 500,000 | — | ↗ |
| 2023-02-28 | Hanley David C. | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 1.94 | 970.0K | 500,000 | — | ↗ |
| 2023-02-28 | Fox Jennifer A. | Officer | A-Award | A | Stock Option (Right to Buy) | 600,000 | 1.94 | 1.16M | 600,000 | — | ↗ |
| 2023-02-21 | NODELMAN OLEG | Director | P-Purchase | A | Class A Common Stock | 53,000 | 1.36 | 72.1K | 12,674,775 | — | ↗ |
| 2023-02-20 | NODELMAN OLEG | Director | P-Purchase | A | Class A Common Stock | 117,100 | 1.36 | 159.5K | 12,621,775 | — | ↗ |
| 2023-02-19 | NODELMAN OLEG | Director | P-Purchase | A | Class A Common Stock | 5,143,000 | 1.26 | 6.46M | 12,504,675 | — | ↗ |
| 2022-12-05 | FALBERG KATHRYN E | Director | P-Purchase | A | Class A Common Stock | 43,000 | 1.95 | 84.0K | 250,000 | — | ↗ |
| 2022-12-02 | FALBERG KATHRYN E | Director | P-Purchase | A | Class A Common Stock | 47,000 | 1.98 | 93.2K | 207,000 | — | ↗ |
| 2022-12-01 | FALBERG KATHRYN E | Director | P-Purchase | A | Class A Common Stock | 84,959 | 1.97 | 167.6K | 160,000 | — | ↗ |
| 2022-11-30 | FALBERG KATHRYN E | Director | P-Purchase | A | Class A Common Stock | 75,041 | 1.85 | 139.1K | 75,041 | — | ↗ |
| 2022-08-29 | Wentworth Kerry | Officer | A-Award | A | Stock Option (Right to Buy) | 252,000 | 0.00 | — | 252,000 | — | ↗ |
| 2022-08-29 | Markel Stacy | Officer | A-Award | A | Stock Option (Right to Buy) | 450,000 | 2.93 | 1.32M | 450,000 | — | ↗ |
| 2022-08-29 | Liu Dongfang | Officer | A-Award | A | Stock Option (Right to Buy) | 315,000 | 0.00 | — | 315,000 | — | ↗ |
| 2022-08-29 | Hattersley Gary | Officer | A-Award | A | Stock Option (Right to Buy) | 400,000 | 2.93 | 1.17M | 400,000 | — | ↗ |
| 2022-08-29 | Hanley David C. | Officer | A-Award | A | Stock Option (Right to Buy) | 450,000 | 0.00 | — | 450,000 | — | ↗ |
| 2022-08-29 | Fox Jennifer A. | Officer | A-Award | A | Stock Option (Right to Buy) | 480,000 | 0.00 | — | 480,000 | — | ↗ |
| 2022-07-15 | Liu Dongfang | Officer | A-Award | A | Stock Option (Right to Buy) | 292,500 | 0.00 | — | 292,500 | — | ↗ |
| 2022-05-23 | Wentworth Kerry | Officer | A-Award | A | Stock Option (Right to Buy) | 247,500 | 0.00 | — | 247,500 | — | ↗ |
| 2022-05-16 | WELCH DANIEL G | Director | A-Award | A | Stock Option (Right to Buy) | 118,784 | 0.00 | — | 118,784 | — | ↗ |
| 2022-05-16 | VERNON W ANTHONY | Director | A-Award | A | Stock Option (Right to Buy) | 118,784 | 0.00 | — | 118,784 | — | ↗ |
| 2022-05-16 | FALBERG KATHRYN E | Director | A-Award | A | Stock Option (Right to Buy) | 118,784 | 0.00 | — | 118,784 | — | ↗ |
| 2022-05-16 | Bazemore Robert B | Director | A-Award | A | Stock Option (Right to Buy) | 118,784 | 4.05 | 481.1K | 118,784 | — | ↗ |
| 2022-05-16 | BLICKENSTAFF KIM D | Director | A-Award | A | Stock Option (Right to Buy) | 118,784 | 0.00 | — | 118,784 | — | ↗ |
| 2022-04-05 | Omega Fund V, L.P. | 10% Owner | S-Sale | D | Common Stock | 2,500,000 | 5.60 | 14.00M | 20,457,340 | — | ↗ |
| 2022-04-05 | Omega Fund V GP Manager, Ltd. | Director | S-Sale | D | Common Stock | 2,500,000 | 5.60 | 14.00M | 20,457,340 | — | ↗ |
| 2022-02-28 | Markel Stacy | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 5.06 | 2.53M | 500,000 | — | ↗ |
| 2022-02-28 | Hung David | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 2,000,000 | 5.06 | 10.12M | 2,000,000 | — | ↗ |
| 2022-02-28 | Hattersley Gary | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 5.06 | 2.53M | 500,000 | — | ↗ |
| 2022-02-28 | Hanley David C. | Officer | A-Award | A | Stock Option (Right to Buy) | 500,000 | 5.06 | 2.53M | 500,000 | — | ↗ |
| 2022-02-28 | Fox Jennifer A. | Officer | A-Award | A | Stock Option (Right to Buy) | 600,000 | 5.06 | 3.04M | 600,000 | — | ↗ |
| 2021-12-15 | Omega Fund V, L.P. | 10% Owner | S-Sale | D | Common Stock | 500,000 | 10.07 | 5.04M | 22,957,340 | — | ↗ |
| 2021-12-07 | Omega Fund V, L.P. | 10% Owner | S-Sale | D | Common Stock | 1,400,000 | 9.80 | 13.72M | 23,457,340 | — | ↗ |
| 2021-11-24 | NODELMAN OLEG | Director | P-Purchase | A | Class A Common Stock | 21,758 | 7.69 | 167.2K | 1,169,241 | — | ↗ |
| 2021-11-23 | Omega Fund V, L.P. | 10% Owner | S-Sale | D | Common Stock | 36 | 9.75 | 351.00 | 24,857,376 | — | ↗ |
| 2021-11-22 | Omega Fund V, L.P. | 10% Owner | S-Sale | D | Common Stock | 295,000 | 9.76 | 2.88M | 24,857,376 | — | ↗ |
| 2021-11-03 | Omega Fund V, L.P. | 10% Owner | S-Sale | D | Common Stock | 2,000,000 | 9.25 | 18.50M | 25,152,376 | — | ↗ |
| 2021-10-29 | WELCH DANIEL G | Director | A-Award | A | Stock Option (Right to Buy) | 45,229 | 9.17 | 414.7K | 45,229 | — | ↗ |
| 2021-10-29 | VERNON W ANTHONY | Director | A-Award | A | Stock Option (Right to Buy) | 45,229 | 9.17 | 414.7K | 45,229 | — | ↗ |
| 2021-10-29 | Omega Fund V, L.P. | 10% Owner | S-Sale | D | Common Stock | 45,000 | 9.27 | 417.2K | 27,152,376 | — | ↗ |
| 2021-10-29 | NODELMAN OLEG | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 45,229 | 9.17 | 414.7K | 45,229 | — | ↗ |
| 2021-10-29 | FALBERG KATHRYN E | Director | A-Award | A | Stock Option (Right to Buy) | 45,229 | 9.17 | 414.7K | 45,229 | — | ↗ |
| 2021-10-29 | Bazemore Robert B | Director | A-Award | A | Stock Option (Right to Buy) | 45,229 | 9.17 | 414.7K | 45,229 | — | ↗ |
| 2021-10-29 | BLICKENSTAFF KIM D | Director | A-Award | A | Stock Option (Right to Buy) | 45,229 | 9.17 | 414.7K | 45,229 | — | ↗ |
| 2021-10-28 | Omega Fund V, L.P. | 10% Owner | S-Sale | D | Common Stock | 1,015,000 | 9.60 | 9.74M | 27,197,376 | — | ↗ |
| 2021-07-31 | NODELMAN OLEG | Director | P-Purchase | A | Class A Common Stock | 56,598 | 8.64 | 489.0K | 7,198,407 | — | ↗ |
| 2021-06-01 | Hanley David C. | Officer | A-Award | A | Stock Option (Right to Buy) | 187,500 | 13.60 | 2.55M | 187,500 | — | ↗ |
| 2021-04-13 | NODELMAN OLEG | Director | P-Purchase | A | Class A Common Stock | 27,534 | 10.27 | 282.8K | 6,990,265 | — | ↗ |
| 2021-04-12 | NODELMAN OLEG | Director | P-Purchase | A | Class A Common Stock | 116,255 | 9.49 | 1.10M | 6,962,731 | — | ↗ |
| 2021-04-09 | NODELMAN OLEG | Director | P-Purchase | A | Class A Common Stock | 262,230 | 10.03 | 2.63M | 6,846,476 | — | ↗ |
| 2021-03-31 | NODELMAN OLEG | Director | S-Sale | A | Class A Common Stock | 151,544 | 10.45 | 1.58M | 1,145,600 | — | ↗ |
| 2021-03-30 | Bazemore Robert B | Director | P-Purchase | A | Class A Common Stock | 5,000 | 9.98 | 49.9K | 5,000 | — | ↗ |
| 2021-03-09 | Hung David | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 224,760 | 12.66 | 2.85M | 224,760 | — | ↗ |
| 2021-03-02 | Hung David | Director / Officer / 10% Owner | J-Other | D | Class A Common Stock | 368,408 | 0.00 | — | 58,281,054 | — | ↗ |
| 2021-02-10 | Yurasov Sergey | Officer | A-Award | A | Stock Option (Right to Buy) | 398,935 | 4.60 | 1.84M | 398,935 | — | ↗ |
| 2021-02-10 | WELCH DANIEL G | Director | A-Award | A | Stock Option (Right to Buy) | 312,750 | 1.74 | 544.2K | 312,750 | — | ↗ |
| 2021-02-10 | VERNON W ANTHONY | Director | A-Award | A | Stock Option (Right to Buy) | 51,703 | 4.60 | 237.8K | 51,703 | — | ↗ |
| 2021-02-10 | Templeman Thomas | Officer | A-Award | A | Stock Option (Right to Buy) | 398,935 | 1.74 | 694.1K | 398,935 | — | ↗ |
| 2021-02-10 | Sharp Shalini | Director | A-Award | A | Class A Common Stock | 10,000 | 10.00 | 100.0K | 35,000 | — | ↗ |
| 2021-02-10 | Omega Fund V, L.P. | 10% Owner | — | D | No securities owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-02-10 | NODELMAN OLEG | Director / 10% Owner | A-Award | A | Class A Common Stock | 2,200,627 | 0.00 | — | 2,200,627 | — | ↗ |
| 2021-02-10 | Markel Stacy | Officer | A-Award | A | Stock Option (Right to Buy) | 398,935 | 4.60 | 1.84M | 398,935 | — | ↗ |
| 2021-02-10 | Hung David | Director / Officer / 10% Owner | A-Award | A | Class A Common Stock | 2,000,000 | 10.00 | 20.00M | 58,645,012 | — | ↗ |
| 2021-02-10 | Hattersley Gary | Officer | A-Award | A | Stock Option (Right to Buy) | 398,935 | 4.60 | 1.84M | 398,935 | — | ↗ |
| 2021-02-10 | Hasnain Faheem | Director | A-Award | A | Class A Common Stock | 30,000 | 10.00 | 300.0K | 55,000 | — | ↗ |
| 2021-02-10 | Fox Jennifer A. | Officer | A-Award | A | Stock Option (Right to Buy) | 558,506 | 4.60 | 2.57M | 558,506 | — | ↗ |
| 2021-02-10 | FALBERG KATHRYN E | Director | — | D | No securities owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-02-10 | COOPER GRAHAM K | Director | M-Exempt | D | Class B Common Stock | 25,000 | 0.00 | — | 0 | — | ↗ |
| 2021-02-10 | Bazemore Robert B | Director | A-Award | A | Stock Option (Right to Buy) | 51,703 | 4.60 | 237.8K | 51,703 | — | ↗ |
| 2021-02-10 | BRADBURY DANIEL | Director | M-Exempt | A | Class A Common Stock | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2021-02-10 | BLICKENSTAFF KIM D | Director | A-Award | A | Stock Option (Right to Buy) | 51,703 | 4.60 | 237.8K | 51,703 | — | ↗ |
| 2020-07-06 | EcoR1 Panacea Holdings, LLC | Director / 10% Owner | P-Purchase | A | Class A common stock | 390,000 | 10.00 | 3.90M | 390,000 | — | ↗ |
| 2020-06-30 | Stout Caroline | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-30 | Sharp Shalini | Director | — | D | Class B common stock | 25,000 | 0.00 | — | 0 | — | ↗ |
| 2020-06-30 | Platshon Scott | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-30 | Perlen Scott | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-30 | PA Co-Investment LLC | 10% Owner | — | D | Class B common stock | 718,750 | 0.00 | — | 0 | — | ↗ |
| 2020-06-30 | Marriott Sarah | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-30 | Hasnain Faheem | Director | — | D | Class B common stock | 25,000 | 0.00 | — | 0 | — | ↗ |
| 2020-06-30 | EcoR1 Panacea Holdings, LLC | Director / 10% Owner | — | D | Class B common stock | 2,775,000 | 0.00 | — | 0 | — | ↗ |
| 2020-06-30 | COOPER GRAHAM K | Director | — | D | Class B common stock | 25,000 | 0.00 | — | 0 | — | ↗ |
| 2020-06-30 | BRADBURY DANIEL | Director | — | D | Class B common stock | 25,000 | 0.00 | — | 0 | — | ↗ |
| 2020-05-23 | Wentworth Kerry | Officer | — | D | No securities owned. | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-02-10 | VERNON W ANTHONY | Director | A-Award | A | Class A Common Stock | 254,100 | 0.00 | — | 254,100 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-7.0K
Shares Outstanding
346.69M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | David Hung, M.D. President and Chief Executive Officer | 650.0K | — | — | 2.67M | 536.3K | 15.8K | 3.88M | 68.99% | ↗ |
| 2 | 2025 | Philippe Sauvage Chief Financial Officer | 510.0K | — | — | 668.7K | 252.5K | 47.6K | 1.48M | 45.22% | ↗ |
| 3 | 2025 | Gary Hattersley, Ph.D. Chief Scientific Officer | 515.1K | — | — | 668.7K | 254.9K | 35.8K | 1.47M | 45.41% | ↗ |
| 4 | 2024 | David Hung, M.D. President and Chief Executive Officer | 609.8K | — | — | 2.52M | 571.9K | 15.7K | 3.72M | 67.79% | ↗ |
| 5 | 2024 | Colleen Sjogren Chief Commercial Officer | 330.0K | — | — | 1.67M | 165.2K | 10.8K | 2.17M | 76.72% | ↗ |
| 6 | 2024 | Gary Hattersley, Ph.D. Chief Scientific Officer | 503.0K | — | — | 630.0K | 251.5K | 22.3K | 1.41M | 44.78% | ↗ |
| 7 | 2024 | Philippe Sauvage Chief Financial Officer | 119.8K | — | — | 997.1K | 66.8K | 7.3K | 1.19M | 83.72% | ↗ |
| 8 | 2023 | David Hung, M.D. President and Chief Executive Officer | 593.0K | — | — | 3.32M | 400.3K | 7.3K | 4.32M | 76.86% | ↗ |
| 9 | 2023 | Gary Hattersley, Ph.D. Chief Scientific Officer | 484.0K | — | — | 664.7K | 174.2K | 36.3K | 1.36M | 48.90% | ↗ |
| 10 | 2023 | David Liu, M.D., Ph.D. Chief Medical Officer | 490.0K | — | — | 664.7K | 176.4K | 10.8K | 1.34M | 49.54% | ↗ |
| 11 | 2022 | David Hung, M.D. President and Chief Executive Officer | 570.0K | — | — | 7.13M | 363.4K | 11.1K | 8.07M | 88.30% | ↗ |
| 12 | 2022 | Jennifer Fox Chief Financial Officer | 546.0K | — | — | 3.14M | 278.5K | 9.8K | 3.97M | 79.01% | ↗ |
| 13 | 2022 | David Hanley, Ph.D. Chief Technical Operations Officer | 430.0K | — | — | 2.72M | 146.2K | 9.8K | 3.31M | 82.28% | ↗ |
| 14 | 2022 | Gary Hattersley, Ph.D. Chief Scientific Officer | 465.0K | — | — | 2.62M | 158.1K | 20.2K | 3.26M | 80.27% | ↗ |
| 15 | 2022 | David Liu, M.D., Ph.D. Chief Medical Officer | 217.7K | — | — | 2.56M | 280.8K | 6.9K | 3.07M | 83.52% | ↗ |
| 16 | 2021 | David Hanley, Ph.D. Chief Technical Operations Officer | 242.1K | 100.0K | — | 4.32M | 146.0K | 9.1K | 4.82M | 89.68% | ↗ |
| 17 | 2021 | David Hung, M.D. President and Chief Executive Officer | 550.0K | — | — | 3.59M | 618.8K | 9.4K | 4.77M | 75.31% | ↗ |
| 18 | 2021 | Jennifer Fox Chief Financial Officer | 525.0K | — | — | — | 472.5K | 9.4K | 1.01M | 0.00% | ↗ |
| 19 | 2020 | Jennifer Fox Chief Financial Officer | 104.0K | 475.0K | — | 3.16M | 141.8K | 1.9K | 3.88M | 81.37% | ↗ |
| 20 | 2020 | David Hung, M.D. President and Chief Executive Officer | 475.0K | — | — | — | 481.0K | 207.2K | 1.16M | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David T. Hung | Founder, President, Chief Executive Officer & Chairman | 1M | — |
| Philippe Sauvage | Chief Financial Officer & Principal Financial Officer | 810.0K | male |
| Gary Hattersley | Chief Scientific Officer | 805.8K | — |
| David Liu | Chief Medical Officer | 677.2K | — |
| Colleen Sjogren | Chief Commercial Officer | 615.8K | female |
| David C. Hanley | Chief Technical Operations Officer | 586.0K | — |
| Stephen Dang | Chief Legal Officer & Corporate Secretary | — | — |
| Kerry A. Wentworth | Chief Regulatory Officer | — | female |
| Moses Makunje | Vice President of Finance and Principal Accounting & Financial Officer | — | male |
| Stacy Markel | Chief People Officer | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NUVB
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
